Activities
Immune-Related Adverse Events
The rapid rate of breakthroughs in immuno-oncology has outpaced continuing education in medicine, leaving pathologists and laboratory teams with a gap in optimal awareness about the core science of pan-tumor immuno-oncology checkpoints, biomarkers, pathways, and therapeutics. A growing body of research has documented the impact of advances in immunotherapy treatments on pathology diagnostics, but new developments have outpaced the laboratory team’s skills in recognizing side effects, especially immune-related adverse events (irAEs), induced by these novel therapies and checkpoint inhibitors. Learn more about these effects with the course shown here.Implementing IO in Community Settings
Immuno-oncology (IO) is showing significant promise in treating cancer patients where other approaches have failed. As breakthroughs in IO continue to revolutionize cancer treatment, pathologists and laboratory professionals—particularly those who practice in smaller, community-based settings — are challenged with keeping informed about, and the implementation of, new testing protocols, diagnosis, and therapeutic treatments. The courses listed here help address the concerns of community based practice.
Find additional resources related to improving immuno-oncology delivery in community practice using the button below.